Eli Lilly’s diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.
Eli Lilly stock can benefit from drugs that tackle the obesity epidemic, both in the short-term and more than a decade into the future, according to Citi.
“In the near-term, we rely on increasing Mounjaro capacity and forthcoming obesity approval to continue to drive share price momentum,” Baum wrote. Lilly’s Mounjaro is competing with Novo Nordisk’s Ozempic in the class of weight-loss drugs known as incretins which have been shown to suppress appetite and reduce food intake. Lilly is lining up two more drug candidates of the same class, retatrutide and orforglipron.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly Is Waiting for Obesity-Drug Approval. How Much It Could Be Worth.Eli Lilly’s diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.
Weiterlesen »
Analysis: Anti-obesity drugs can be boost for food makers, investors sayThe growth in demand for appetite suppressing anti-obesity drugs like Novo Nordisk's (NOVOb.CO) Wegovy presents opportunities for food manufacturers and the market's initially downbeat reaction may be overdone, investors say.
Weiterlesen »
The Hollywood actors strike hits 100 days. Why hasn't a deal been reached and what's next?The historic Lilly house is open for guests who want a spooky experience.
Weiterlesen »
JSO: Woman shot twice while waiting for Uber in Lake Forest areaJSO is investigating after a woman was shot twice on Palmdale Street.
Weiterlesen »
Woman shot while waiting for Uber in Northwest Jacksonville: policeA woman in her late 30s was taken to a hospital with non-life-threatening gunshot wounds Monday morning after she was shot while waiting for an Uber in Northwest Jacksonville.
Weiterlesen »